Dialysis industry news

Stories from the dialysis comunity across the globe.

[Experience in nephron-sparing surgery in patients with small renal tumors]. - UroToday PDF Print

BACKGROUND - Nephron -sparing surgery is currently the treatment of choice for surgical removal of solid renal tumours smaller than 7 cm, in the case of a solitary kidney, bilateral renal tumours or the presence of chronic renal failure.

MATERIAL AND METHODS - An observational, descriptive, retrospective and cross-sectional study was conducted. The variables evaluated were: age at diagnosis, gender, intraoperative blood loss, operative time, preoperative tumour size, hospital stay, pathology report, pTNM classification, Fuhrman nuclear grade, pre- and post-operative creatinine, monitoring for cancer. All were analysed using SPSS v 22.

RESULTS - The study included 28 patients, 14 male and 14 women, with a mean age 52.3 years. The approach was lumbotomy in all patients. The mean hospital stay was 4.1 days. Mean perioperative bleeding loss was 380.3 ml. The mean preoperative creatinine was 0.96 mg/dl, with a post-operative mean of 1.12 mg/dl. Histopathology reported, 23 clear cell tumours, 2 angiomyolipomas, 2 oncocytomas, and 1 haemorrhagic cyst. Tumour staging was performed on 14 patients, with 13 patients T1bN0M0, and 1 patient T2aN0M0. In clear cell tumours, Fuhrman nuclear grade 2 was present in 16 patients and 7 patients were Fuhrman grade 3.

CONCLUSIONS - Nephron sparing surgery is the choice procedure of choice in patients with small renal tumours, with good functional results without significant alteration in renal function. Outcome is optimal, with a low incidence of complications.

Cir Cir. 2015 Jun 22. pii: S0009-7411(15)00090-0. doi: 10.1016/j.circir.2015.05.016. [Epub ahead of print]

[Article in Spanish]
Sánchez-Coral M1, Báez-Reyes JR2, García-Cano E3, Quintero-León MÁ1, Cárdenas-Rodríguez E1, Priego-Niño A1.

1 Servicio de Urología, Unidad Médica de Alta Especialidad, General Manuel Ávila Camacho, Instituto Mexicano del Seguro Social Puebla, Puebla, México.
2 Servicio de Urología, Unidad Médica de Alta Especialidad, General Manuel Ávila Camacho, Instituto Mexicano del Seguro Social Puebla, Puebla, México.
3 Servicio de Cirugía General, Unidad Médica de Alta Especialidad, General Manuel Ávila Camacho, Instituto Mexicano del Seguro Social Puebla, Puebla, México.


PET/Computed Tomography in Renal, Bladder, and Testicular Cancer. - UroToday PDF Print

Imaging plays an important role in the clinical management of cancer patients. Hybrid imaging with PET/computed tomography (CT) is having a broad impact in oncology, and in recent years PET/CT is beginning to have an impact in urooncology.

In both bladder and renal cancers, there is a need to study the efficacy of other tracers than F-18 fluorodeoxyglucose (FDG), particularly tracers with limited renal excretion. Thus, new tracers are being introduced. This review focuses on the clinical role of FDG and other PET agents in renal, bladder, and testicular cancers.

PET Clin. 2015 Jul;10(3):361-74. doi: 10.1016/j.cpet.2015.03.002. Epub 2015 Apr 24.

Bouchelouche K1, Choyke PL2.

1 Department of Nuclear Medicine & PET Centre, Aarhus University Hospital, Skejby, Brendstrupgaardsvej 100, Aarhus DK-8200, Denmark.
2 Molecular Imaging Program, Building 10, Room B3B6B9F, Center for Cancer Research, National Cancer Institute (NCI), Bethesda, MD, USA.


NxStage Medical, Inc. Analyst Rating Update - American Trade Journal PDF Print

NxStage Medical, Inc. (NASDAQ:NXTM) has received a buy rating for the short term, according to the latest rank of 2 from research firm, Zacks. The company received an average rating of 2 from 6 analysts. 1 analyst have rated it as strong sell. 4 have rated it as a strong buy. 1 analysts have rated the company at hold.

Many analysts have commented on the company rating. In a research note released to the investors, Canaccord Genuity maintains its rating on NxStage Medical, Inc. (NASDAQ:NXTM). Investors must note that the brokerage house has a Buy rating on the shares of the company. The Equity Firm raises its price target from $24 per share to $27 per share. The rating by the firm was issued on February 27, 2015. NxStage Medical, Inc. (NASDAQ:NXTM) should head towards $21 per share according to 4 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $15 per share. The higher price estimate target is at $24 according to the Analysts. NxStage Medical, Inc. (NASDAQ:NXTM) rose 0.49% or 0.09 points on Monday and made its way into the gainers of the day. After trading began at $18.15 the stock was seen hitting $18.43 as a peak level and $18.01 as the lowest level. The stock ended up at $18.36. The daily volume was measured at 569,733 shares. The 52-week high of the share price is $19.63 and the 52-week low is $11.5. The company has a market cap of $1,165 million. Shares of Nxstage Medical, Inc. rose by 2.63% in the last five trading days and 29.2% for the last 4 weeks. Nxstage Medical, Inc. is up 11.88% in the last 3-month period. Year-to-Date the stock performance stands at 2.4%. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the (President) of Nxstage Medical, Inc., Turk Joseph E Jr had sold 3,252 shares worth of $57,690 in a transaction dated August 12, 2015. In this transaction, 3,252 shares were sold at $17.74 per share. NxStage Medical, Inc. (NxStage) is a medical device company that develops, manufactures and markets products for the treatment of kidney failure, fluid overload and related blood treatments and procedures. The Companys primary product is the NxStage System One (System One). It also sells needles and blood tubing sets primarily to dialysis clinics for the treatment of end-stage renal disease (ESRD). It operates in two segments: System One and In-Center. It distributes its products in three markets: home, critical care and in-center. In the System One segment it derives its revenues from the sale and rental of the System One and PureFlow SL equipment, and the sale of disposable products in the home and critical care markets. In the In-Center segment, it derives its revenues from the sale of blood tubing sets and needles for hemodialysis primarily for the treatment of ESRD patients at dialysis centers and needles for apheresis, which is referred to as the in-center market.


Optimizing ECD graft outcomes - Nature.com PDF Print

Optimizing ECD graft outcomes
A strategy of allocating extended criteria donor (ECD) kidneys only to recipients without anti-HLA donor-specific antibodies (DSAs) and reducing cold ischaemia time to <12 h could significantly improve the long-term outcomes of ECD transplantation, ...


Anya Pogharian, Montreal teen inventor, takes portable dialysis machine to the ... - CBC.ca PDF Print

Anya Pogharian never thought her high school science fair project would bring her international attention and job opportunities from around the world.

"India, Australia, Russia, Armenia — like everywhere, just everywhere. South America. You name it, I got a message from there," said Pogharian.

Ontario-based health-care firm Baxter Corp. offered to sponsor her and provide her with filters.

Pogharian said she heard from dialysis patients right across Canada, congratulating her and wishing her success.

She was 17 when she invented a cheap, portable dialysis machine.

CBC News first published her story in February. Pogharian was inspired by volunteering at a hospital dialysis unit.

Dialysis is the process of cleaning waste from the blood. It's typically used for people who have kidney disease. The treatment takes about four hours a couple of times per week.

CBC's story received tens of thousands of hits, and the international exposure pushed Pogharian to take her invention to the next level.

?Pogharian said she's been working non-stop to improve her portable machine, which costs about $500 to build. Currently, dialysis machines cost about $30,000.

"To date, I have been working crazy hours on this project...I've stopped counting."

25 minutes

Héma-Québec, the non-profit organization that manages the province's blood products and human tissue and ensures the safety of blood supply, offered her an internship, allowing her to try her prototype on real blood.

Pogharian and her team hoped it would filter four litres of blood in two and half hours. It took only 25 minutes.

She said its efficacy, simplicity and portability make it ideal for the developing world and in disaster zones.

It could also help people closer to home.

Patient Philippe Ouaknine said dialysis treatments, which often took several hours every other day, kept him from working and seeing his family.

"My mother lives outside the city. So we had to time [it to] make sure that I was coming back for my treatment."

Home units do exist but are expensive and rarely available through Quebec's health care system.

Ouaknine said Pogharian's invention would revolutionize patients' lives.

That's exactly what Pogharian is hoping for.

"I just know how difficult it is. And I can't even imagine having to live with that," she said.

Pogharian expects her machine to hit the market in a couple of years.


<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>

Page 13 of 4210
Share |
Copyright © 2018 Global Dialysis. All Rights Reserved.